Indee Labs

Sustainable Development Goals

Challenges

Reach Humanity Scale Healthcare

Team

Mike Nicholls

Co-Investors

Company Briefing

Indee Labs is developing Hydropore the next generation manufacturing process for Immunotherapy Cancer Treatments.

Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the power of microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene-editing complexes to immune cells in a matter of seconds, yielding millions of high quality cells with negligible impact to cell viability and function. Hydropore™ bypasses the challenges and limitations of viral transduction and traditional transfection via electroporation, allowing companies to accelerate their research goals from discovery to manufacturing.

Website

Related companies

Coviu
Cylite
Inventia
Prospection